Get to know our company
Biocelect is a Sydney-based company that sources, in-licences and commercialises biopharmaceutical products for Australia, New Zealand and the South Pacific that address unmet medical needs of patients. In Australia, Biocelect has just registered its first specialty prescription product, KODATEF (tafenoquine), the first new drug molecule for malaria prevention in 20 years. Biocelect launched KODATEF (tafenoquine) in early 2019. Being an agile company, we can provide a range of bespoke partnering solutions for companies wanting to distribute their products in Australia and the region. Biocelect has an experienced and seasoned team with many years of experience in the global pharmaceutical industry. Biocelect also has the ability to draw on the extensive capability of its sister company, Biointelect, including its deep knowledge of market evaluation and market access in Australia and beyond. This allows Biocelect to provide all the functions of a bigger company, ensuring the success of the product and ultimately meeting the needs of the patient.